Calyxt (NASDAQ: CLXT) CEO Jim Blome joined Steve Darling from Proactive with the news the company has made some major change in their strategy and business model that set the company up for major growth.
Blome discusses what changes have been made and when investors may see results. Blome also told Proactive about their proprietary gene-editing tool Talen and how they plan on taking it to market.
Price: 5.41 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Calyxt named herein, including the promotion by the Company of Calyxt in any Content on the Site, the Company receives from said issuer annual...
FOR OUR FULL DISCLAIMER CLICK HERE
Calyxt (NASDAQ: CLXT) CEO Jim Blome joined Steve Darling from Proactive to discuss their year-end numbers and accomplishments. Blome discussing why he felt 2019 really set the company up for success in the future. Blome also told Proactive what the plan is for 2020 and how their R&D...
Retail & consumer
Thunderbird Entertainment releases fall slate of shows on...
Health
Prev article
